1. Kessler RC, Stang PE, Wittchen HU, Ustun TB, Roy-Burne PP, Walters EE. Lifetime panic-depression comorbidity in the National Comorbidity Survey. Arch Gen Psychiatry. 1998;55: 801-8.
2. Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2006; 63: 415-24.
3. Schumacher J1, Kristensen AS, Wendland JR, Nöthen MM, Mors O, McMahon FJ. The genetics of panic disorder. J Med Genet. 2011;48:361-8.
4. Middeldorp CM, Birley AJ, Cath DC, Gillespie NA, Willemsen G, Statham DJl. Familial clustering of major depression and anxiety disorders in Australian and Dutch twins and siblings. Twin Res Hum Genet. 2005; 8: 609-15
5. Maron E, Lang A, Tasa G, Liivlaid L, Tõru I, Must, A, et al. Associations between serotonin-related gene polymorphisms and panic disorder. Int J Neuropsychopharmacol. 2005; 8: 261-6.
6. Kim W, Choi YH, Yoon KS, Liivlaid L, Tõru I, Must A, et al. Tryptophan hydroxylase and serotonin transporter gene polymorphism does not affect the diagnosis, clinical features and treatment outcome of panic disorder in the Korean population. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 30:1413-8.
7. Strug LJ, Suresh R, Fyer AJ, Talati A, Adams PB, Li W, et al. Panic disorder is associated with the serotonin transporter gene (SLC6A4) but not the promoter region (5-HTTLPR). Mol Psychiatry. 2010;15:166-76.
8. Rothe C, Koszycki D, Bradwejn J, King N, De Luca V, Shaikh S, et al. Association study of serotonin-2A receptor gene polymorphism and panic disorder in patients from Canada and Germany. Neurosci Lett. 2004;363:276-9.
9. Rothe C, Koszycki D, Bradwejn J, King N, De luca, V, Tharmalingam S,et al. Association of the Val158Met catechol O-methyltransferase genetic polymorphism with panic disorder. Neuropsychopharmacology. 2006; 31:2237-42.
10. Choi WS, Lee BH, Yang JC, Kim YK. Association Study between 5-HT1A Receptor Gene C(-1019)G Polymorphism and Panic Disorder in a Korean Population. Psychiatry Investig. 2010;7:141-6.
11 Yoon HK, Yang JC, Lee HJ, Kim YK. The association between serotonin-related gene polymorphisms and panic disorder. J Anxiety Disord. 2008; 22:1529-34.
12. Annerbrink K, Westberg L, Olsson M, Olsson M, Allgulander S, Andersch S, et al. Association between the catechol-O-methyltransferase Val158Met polymorphism and panic disorder: a replication. Psychiatry Res. 2010;178:196-8.
13. Karacetin G, Bayoglu B, Cengiz M, Demira T, Kocabasoglu N, Uysal O, et al. Serotonin-2A receptor and catechol-O-methyltransferase polymorphisms in panic disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2012;36:5-10.
14. Schumacher J, Deckert J. Serotonin transporter polymorphisms and panic disorder. Genome Med. 2010; 2: 40.
15. Watanabe T, Ishiguro S, Aoki A, Ueda M, Hayashi Y, Akiyama K, et al. Genetic Polymorphism of 1019C/G (rs6295) Promoter of Serotonin 1A Receptor and Catechol-O-Methyltransferase in Panic Disorder. Psychiatry Investig. 2017; 14: 86-92.
16. Niitsu T, Fabbri C, Bentini F, Serretti A. Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 45: 183-94.
17. Nonen S, Kato M, Takekita Y, Wakeno M, Sakai S, Serretti A, et al. Polymorphism of rs3813034 in Serotonin Transporter Gene SLC6A4 Is Associated With the Selective Serotonin and Serotonin-Norepinephrine Reuptake Inhibitor Response in Depressive Disorder: Sequencing Analysis of SLC6A4. J Clin Psychopharmacol. 2016;36:27-31.
18. Andre K, Kampman O, Illi A, Viikki M, Setälä-Soikkeli E, Mononen N,et al. SERT and NET polymorphisms, temperament and antidepressant response. Nord J Psychiatry. 2015;69:531-8.
19. Yeh YW, Chen CJ, Jang FL, Kuo SC, Chen CY, Liang CS, et al. SLC6A2 variants may predict remission from major depression after venlafaxine treatment in Han Chinese population. J Psychiatr Res. 2015;61:33-9.
20. Camarena B, Álvarez-Icaza D, Hernández S, Aguilar A, Münch L, Martínez C, et al. Association Study Between Serotonin Transporter Gene and Fluoxetine Response in Mexican Patients With Major Depressive Disorder. Clin Neuropharmacol. 2019;42:9-13.
21. Mochcovitch MD, Nardi AE. Selective serotonin-reuptake inhibitors in the treatment of panic disorder: a systematic review of placebo-controlled studies. Expert Rev Neurother. 2010;10:1285-93.
22. Pohl RB, Wolkow RM, Clary CM. Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry. 1998;155:1189-95.
23. Bandelow B, Behnke K, Lenoir S, Hendriks GJ, Alkin T, Goebel C, et al. Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blindnoninferiority comparison. J Clin Psychiatry. 2004; 65:405-13.
24. Kamijima K, Kuboki T, Kumano H, Burt T, Cohen G, Arano I, et al. A placebo-controlled, randomized withdrawal study of sertraline for panic disorder in Japan. Int Clin Psychopharmacol. 2005; 20: 265-73.
25. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) (Clinical Version). American Psy-
chiatric Press Inc, Washington DC, USA. 1997.
26. Shear MK, Brown TA, Barlow DH, Money R, Sholomskas DE, Woods SW, et al. Multicenter collaborative panic disorder severity scale. Am J Psychiatry. 1997; 154:1571-5.
27. Xiong HF, Li ZJ, Han HY, Xu ZY, Guo ZH, Yao SM, et al. Panic disorder severity scale-chinese version: reliability and validity. Chin J Psychiatry. 2012;45:285-288.
28. Furukawa TA, Katherine Shear M, Barlow DH, Gorman J M, Woods S W, Money R, et al. Evidence-based guidelines for interpretation of the Panic disorder severity scale. Depress Anxiety. 2009; 26:922–929.
29. Lesch KP, Gutknecht L. Pharmacogenetics of the serotonin transporter. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:1062-73.
30. Maron E, Shlik J. Serotonin function in panic disorder: important, but why? Neuropsychopharmacology. 2006;31:1-11.
31. Bodden C, Richter SH, Schreiber RS, Kloke V, Gerß J, Palme R, et al. Benefits of adversity?! How life history affects the behavioral profile of mice varying in serotonin transporter genotype. Front Behav Neurosci. 2015;9:47.
32. Meyer N, Richter SH, Schreiber RS, Kloke V, Kaiser S, Lesch KP, et al. The Unexpected Effects of Beneficial and Adverse Social Experiences during Adolescence on Anxiety and Aggression and Their Modulation by Genotype. Front Behav Neurosci. 2016;10:97.
33. Line SJ, Barkus C, Coyle C, Jennings KA, Deacon RM, Lesch KP, et al. Opposing alterations in anxiety and species-typical behaviours in serotonin transporter overexpressor and knockout mice. Eur Neuropsychopharmacol. 2011; 21:108-16.
34. Rao H, Gillihan SJ, Wang J, Korczykowski M, Sankoorikal GM, Kaercher KA, et al. Genetic variation in serotonin transporter alters resting brain function in healthy individuals. Biol Psychiatry. 2007; 62:600-6.
35. Domschke K, Braun M, Ohrmann P, Suslow T, Kugel H, Bauer J, et al. Association of the functional -1019C/G 5-HT1A polymorphism with prefrontal cortex and amygdala activation measured with 3 T fMRI in panic disorder. Int J Neuropsychopharmacol. 2006; 9:349-55.
36. Pfleiderer B, Zinkirciran S, Arolt V, Heindel W, Deckert J, Domschke K. fMRI amygdala activation during a spontaneous panic attack in a patient with panic disorder. World J Biol Psychiatry. 2007;8:269-72.
37. Wittmann A, Schlagenhauf F, John T, Guhn A, Rehbein H, Siegmund A, et al. A new paradigm (Westphal-Paradigm) to study the neural correlates of panic disorder with agoraphobia. Eur Arch Psychiatry Clin Neurosci. 2011; 261:185-94.
38. Gyawali S, Subaran R, Weissman MM, Hershkowitz D, McKenna MC, Talati A, et al. Association of a polyadenylation polymorphism in the serotonin transporter and panic disorder.Biol Psychiatry. 2010;67:331-8.
39. Howe AS, Buttenschøn HN, Bani-Fatemi A, Maron E, Otowa T, Erhardt A, et al. Candidate genes in panic disorder: meta-analyses of 23 common variants in major anxiogenic pathways. Mol Psychiatry. 2016; 21:665-79.
40. Maron E, Nikopensius T, Kõks S, Altmäe S, Heinaste E, Vabrit K, et al.
Association study of 90 candidategene polymorphisms in panic disorder. Psychiatr Genet. 2005;15:17-24.
41. Saiz PA, Martínez-Barrondo S, García-Portilla MP, Corcoran P, Morales B,
Bascaran MT, et al. Role of serotonergic polymorphisms in the clinical severity of the panic disorder. Rev Psiquiatr Salud Ment. 2009;2:35-41.
42. Heils A, Teufel A, Petri S, Stöber G, Riederer P, Bengel D, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem. 1996; 66: 2621-4.
43. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996; 274:1527–31.
44. Hariri AR, Mattay VS, Tessitore A, Kolachana B, Fera F, Goldman D, et al. Serotonin transporter genetic variation and the response of the human amygdala. Science. 2002; 297:400-3.
45. Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive–compulsive disorder. Am J Hum Genet. 2006;78:815–26
46. Knuts I, Esquivel G, Kenis G, Overbeek T, Leibold N, Goossens L, et al. Therapygenetics: 5-HTTLPR genotype predicts the response to exposure therapy for agoraphobia. Eur Neuropsychopharmacol. 2014; 24:1222-8.
47. Umene-Nakano W, Yoshimura R, Ueda N, Suzuki A, Ikenouchi-Sugita A, Hori H, et al. Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism. J Psychopharmacol. 2010; 24:1764-71.
48. Safarinejad MR. Analysis of association between the 5-HTTLPR and STin2 polymorphisms in the serotonin-transporter gene and clinical response to a selective serotonin reuptake inhibitor (sertraline) in patients with premature ejaculation. BJU Int. 2010;105:73-8.
49. Yevtushenko OO, Oros MM, Reynolds GP. Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism. J Affect Disord. 2010;123:308-11.
50. Dogan O, Yuksel N, Ergun MA, Yilmaz A, Ilhan MN, Karslioglu HE, et al. Serotonin transporter gene polymorphisms and sertraline response in major depression patients. Genet Test. 2008;12: 225-31.
51. He Q, Yuan Z, Liu Y, Zhang J, Yan H, Shen L, et al. Correlation between cytochrome P450 2C19 genetic polymorphism and treatment response to escitalopram in panic disorder. Pharmacogenet Genomics. 2017; 27: 279-84.
52. Lisoway AJ, Zai CC, Tiwari AK, Kennedy JL. DNA methylation and clinical response to antidepressant medication in major depressive disorder: A review and recommendations. Neurosci Lett. 2018; 669:14-23.
53. Ishiguro S, Watanabe T, Ueda M, Saeki Y, Hayashi Y, Akiyama K, et al. Determinants of pharmacodynamic trajectory of the therapeutic response to paroxetine in Japanese patients with panic disorder. Eur J Clin Pharmacol. 2011;67:1213-21.
54. Woo JM, Yoon KS, Choi YH, Oh KS, Lee YS, Yu BH. The association between panic disorder and the L/L genotype of catechol-O-methyltransferase. J Psychiatr Res. 2004; 38:365-70.
55. Porcelli S, Fabbri C, Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol. 2012; 22:239-58.